Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Naomi N. Barak"'
1
Crystal Structure and Functional Analysis of the Protein Disulfide Isomerase-Related Protein ERp29
Autor: Piotr Neumann, Madhumati Sevvana, Milton T. Stubbs, Mike Schutkowski, David M. Ferrari, Kai Naumann, Gunter Fischer, Naomi N. Barak, Miroslav Malesevic, Heike Reichardt
Publikováno v: Journal of Molecular Biology. 385:1630-1642
The protein disulfide isomerase-related protein ERp29 is a putative chaperone involved in processing and secretion of secretory proteins. Until now, however, both the structure and the exact nature of interacting substrates remained unclear. We provi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c7856a6cf95eecf54a3cdfd2d12035b
https://doi.org/10.1016/j.jmb.2008.11.052
Zobrazit plný text záznamu
2
Regulation of endosomal membrane traffic by a Gadkin/AP-1/kinesin KIF5 complex
Autor: Tanja Maritzen, Laura Doglio, Volker Haucke, Michael R. Schmidt, Viktoria Kukhtina, Holger M. Strauss, Naomi N. Barak, Carlos G. Dotti, Victoria A. Higman, Hartmut Oschkinat
Publikováno v: Proceedings of the National Academy of Sciences of the United States of America, 106(36): 15344–15349
Endosomes and endosomal vesicles (EVs) rapidly move along cytoskeletal filaments allowing them to exchange proteins and lipids between different endosomal compartments, lysosomes, the trans-Golgi network (TGN), and the plasma membrane. The precise me
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e454f5a7662478d53a10f735b16eef18
https://repository.publisso.de/resource/frl:6403192
Zobrazit plný text záznamu
3
Conserved structural and functional properties of D-domain containing redox-active and -inactive protein disulfide isomerase-related protein chaperones
Autor: Daojun Diao, David M. Ferrari, Naomi N. Barak, Undine Lippert
Publikováno v: Journal of Biological Chemistry
The structure and mode of binding of the endoplasmic reticulum protein disulfide isomerase-related proteins to their substrates is currently a focus of intensive research. We have recently determined the crystal structure of the Drosophila melanogast
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceea68be81195496a321ad0d31be2ec7
https://pubmed.ncbi.nlm.nih.gov/17296603
Zobrazit plný text záznamu
4
Akademický článek
Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo -Active KAT6AB Inhibitor.
Autor: Ter Laak A; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Hillig RC; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Ferrara SJ; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, 415 Main St., Cambridge, Massachusetts 02142, United States., Korr D; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Barak N; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Lienau P; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Herbert S; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Fernández-Montalván AE; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Neuhaus R; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Gorjánácz M; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Puetter V; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Badock V; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Bone W; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Strathdee C; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, 415 Main St., Cambridge, Massachusetts 02142, United States., Siegel F; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Schatz C; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Nowak-Reppel K; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Doehr O; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Gradl S; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Hartung IV; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany., Meyerson M; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, 415 Main St., Cambridge, Massachusetts 02142, United States., Bouché L; Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Oct 25. Date of Electronic Publication: 2024 Oct 25.
Zobrazit plný text záznamu
5
Akademický článek
A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy.
Autor: Böhnke N; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Berger M; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Griebenow N; Bayer AG, Pharmaceuticals, Wuppertal 42113, Germany., Rottmann A; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Erkelenz M; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Hammer S; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Berndt S; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Günther J; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Wengner AM; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Stelte-Ludwig B; Bayer AG, Pharmaceuticals, Wuppertal 42113, Germany., Mahlert C; Bayer AG, Pharmaceuticals, Wuppertal 42113, Germany., Greven S; Bayer AG, Pharmaceuticals, Wuppertal 42113, Germany., Dietz L; Bayer AG, Pharmaceuticals, Wuppertal 42113, Germany., Jörißen H; Bayer AG, Pharmaceuticals, Wuppertal 42113, Germany., Barak N; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Bömer U; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Hillig RC; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Eberspaecher U; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Weiske J; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Giese A; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Mumberg D; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Nising CF; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Weinmann H; Bayer AG, Pharmaceuticals, Berlin 13353, Germany., Sommer A; Bayer AG, Pharmaceuticals, Berlin 13353, Germany.
Publikováno v: Bioconjugate chemistry [Bioconjug Chem] 2022 Jun 15; Vol. 33 (6), pp. 1210-1221. Date of Electronic Publication: 2022 Jun 03.
Zobrazit plný text záznamu
6
Akademický článek
Identification of Small Molecules that Modulate Mutant p53 Condensation.
Autor: Lemos C; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Schulze L; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Weiske J; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Meyer H; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Braeuer N; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Barak N; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Eberspächer U; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Werbeck N; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Stresemann C; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Lange M; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Lesche R; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Zablowsky N; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Juenemann K; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Kamburov A; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Luh LM; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Leissing TM; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Mortier J; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Steckel M; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Steuber H; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Eis K; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Eheim A; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany., Steigemann P; Bayer AG Research and Development, Pharmaceuticals, Müllerstr. 178, 13342 Berlin, Germany.
Publikováno v: IScience [iScience] 2020 Sep 01; Vol. 23 (9), pp. 101517. Date of Electronic Publication: 2020 Sep 01 (Print Publication: 2020).
Zobrazit plný text záznamu
7
Akademický článek
Concentration Dependence of the Unbound Partition Coefficient Kp uu and Its Application to Correct for Exposure-Related Discrepancies between Biochemical and Cellular Potency of KAT6A Inhibitors.
Autor: Trünkle C; Bayer AG, Pharma R&D, Translational Sciences, Research Pharmacokinetics, Berlin, Germany (C.T., C.L., A.R.); Bayer AG, Pharma R&D, Therapeutic Compound Research, Berlin, Germany (D.K.); Bayer AG, Pharma R&D, Small Molecule Innovation, Berlin, Germany (L.B., N.B., A.F.-M) and Technische Universität Berlin, Institut für Chemie, Berlin, Germany (C.T., R.D.S.)., Lechner C; Bayer AG, Pharma R&D, Translational Sciences, Research Pharmacokinetics, Berlin, Germany (C.T., C.L., A.R.); Bayer AG, Pharma R&D, Therapeutic Compound Research, Berlin, Germany (D.K.); Bayer AG, Pharma R&D, Small Molecule Innovation, Berlin, Germany (L.B., N.B., A.F.-M) and Technische Universität Berlin, Institut für Chemie, Berlin, Germany (C.T., R.D.S.)., Korr D; Bayer AG, Pharma R&D, Translational Sciences, Research Pharmacokinetics, Berlin, Germany (C.T., C.L., A.R.); Bayer AG, Pharma R&D, Therapeutic Compound Research, Berlin, Germany (D.K.); Bayer AG, Pharma R&D, Small Molecule Innovation, Berlin, Germany (L.B., N.B., A.F.-M) and Technische Universität Berlin, Institut für Chemie, Berlin, Germany (C.T., R.D.S.)., Bouché L; Bayer AG, Pharma R&D, Translational Sciences, Research Pharmacokinetics, Berlin, Germany (C.T., C.L., A.R.); Bayer AG, Pharma R&D, Therapeutic Compound Research, Berlin, Germany (D.K.); Bayer AG, Pharma R&D, Small Molecule Innovation, Berlin, Germany (L.B., N.B., A.F.-M) and Technische Universität Berlin, Institut für Chemie, Berlin, Germany (C.T., R.D.S.)., Barak N; Bayer AG, Pharma R&D, Translational Sciences, Research Pharmacokinetics, Berlin, Germany (C.T., C.L., A.R.); Bayer AG, Pharma R&D, Therapeutic Compound Research, Berlin, Germany (D.K.); Bayer AG, Pharma R&D, Small Molecule Innovation, Berlin, Germany (L.B., N.B., A.F.-M) and Technische Universität Berlin, Institut für Chemie, Berlin, Germany (C.T., R.D.S.)., Fernández-Montalván A; Bayer AG, Pharma R&D, Translational Sciences, Research Pharmacokinetics, Berlin, Germany (C.T., C.L., A.R.); Bayer AG, Pharma R&D, Therapeutic Compound Research, Berlin, Germany (D.K.); Bayer AG, Pharma R&D, Small Molecule Innovation, Berlin, Germany (L.B., N.B., A.F.-M) and Technische Universität Berlin, Institut für Chemie, Berlin, Germany (C.T., R.D.S.)., Süssmuth RD; Bayer AG, Pharma R&D, Translational Sciences, Research Pharmacokinetics, Berlin, Germany (C.T., C.L., A.R.); Bayer AG, Pharma R&D, Therapeutic Compound Research, Berlin, Germany (D.K.); Bayer AG, Pharma R&D, Small Molecule Innovation, Berlin, Germany (L.B., N.B., A.F.-M) and Technische Universität Berlin, Institut für Chemie, Berlin, Germany (C.T., R.D.S.)., Reichel A; Bayer AG, Pharma R&D, Translational Sciences, Research Pharmacokinetics, Berlin, Germany (C.T., C.L., A.R.); Bayer AG, Pharma R&D, Therapeutic Compound Research, Berlin, Germany (D.K.); Bayer AG, Pharma R&D, Small Molecule Innovation, Berlin, Germany (L.B., N.B., A.F.-M) and Technische Universität Berlin, Institut für Chemie, Berlin, Germany (C.T., R.D.S.) andreas.reichel@bayer.com.
Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2020 Jul; Vol. 48 (7), pp. 553-562. Date of Electronic Publication: 2020 May 01.
Zobrazit plný text záznamu
8
Akademický článek
Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
Autor: Eggert E; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Hillig RC; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Koehr S; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Stöckigt D; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Weiske J; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Barak N; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Mowat J; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Brumby T; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Christ CD; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Ter Laak A; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Lang T; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Fernandez-Montalvan AE; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Badock V; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Weinmann H; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Hartung IV; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Barsyte-Lovejoy D; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Szewczyk M; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Kennedy S; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Li F; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Vedadi M; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada.; Department of Pharmacology and Toxicology, University of Toronto , Toronto, Ontario M5S 1A8, Canada., Brown PJ; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Santhakumar V; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada., Arrowsmith CH; Structural Genomics Consortium, University of Toronto , Toronto, Ontario M5G 1L7, Canada.; Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto , Toronto, Ontario M5G 2M9, Canada., Stellfeld T; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany., Stresemann C; Drug Discovery, BAYER Pharma AG , Muellerstrasse 178, 13353 Berlin, Germany.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2016 May 26; Vol. 59 (10), pp. 4578-600. Date of Electronic Publication: 2016 May 03.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje